XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Cash flows used in operating activities:              
Net loss $ (3,219) $ (4,805) $ (5,219) $ (4,116) $ (9,506) $ (14,617)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         477 460  
Amortization of deferred financing costs and debt discount         160 309  
Stock issued for research and development         75    
Loss on disposal of property and equipment         2    
Stock-based compensation expense         428 476  
Change in fair value of derivative instruments           (1)  
Amortization of operating lease right-of-use assets         86 66  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Grant Receivable         (91) 73  
Other assets         3,190 642  
Accounts payable and accrued expenses         (4,061) 1,955  
Change in operating lease liabilities         (87) (101)  
Deferred grant liability         (1,643)    
Net cash used in operating activities         (10,970) (10,738)  
Cash flows used in investing activities:              
Purchases of property and equipment         (118) (381)  
Purchase of intangible assets           (117)  
In process research and development acquired           (250)  
Net cash used in investing activities         (118) (748)  
Cash flows from financing activities:              
Principal payments of term loan obligation         (1,206) (1,206)  
Proceeds from sale of common stock, net of offering cost of $0.2 million and $0.7 million, respectively         5,180 14,558  
Net cash provided by financing activities         3,974 13,352  
Net increase (decrease) in cash and cash equivalents         (7,114) 1,866  
Cash and cash equivalents at beginning of period   $ 18,120   $ 18,400 18,120 18,400 $ 18,400
Cash and cash equivalents at end of period $ 11,006   $ 20,266   11,006 20,266 $ 18,120
Cash paid during period for:              
Interest         186 248  
Supplemental schedule of non-cash investing and financing activities:              
Unpaid offering cost         1 $ 68  
Right-of-use assets acquired by assuming operating lease liabilities         71    
Common stock issued in payment for in process research and development         $ 75